And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...

President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...

Friday - Shares of Verona Pharma (NASDAQ:VRNA) received a positive outlook from Roth/MKM as the firm initiated coverage with a Buy rating and a 12-month price target of $68. The bullish stance is ...

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods gained and the significance of the new drugs and biologics that these ...